Long intergenic noncoding RNA 299 methylation in peripheral blood is a biomarker for triple-negative breast cancer-Reference-Cited by-同舟云学术

Long intergenic noncoding RNA 299 methylation in peripheral blood is a biomarker for triple-negative breast cancer

Published:2019-01 Issue:1 Volume:11 Page:81-93
ISSN:1750-1911
Container-title:Epigenomics
language:en
Short-container-title:Epigenomics

Author:

Bermejo Justo L¹,Huang Guanmengqian²,Manoochehri Mehdi²,Mesa Karen G¹²,Schick Matthias³,Silos Rosa G¹,Ko Yon-Dschun⁴,Brüning Thomas⁵,Brauch Hiltrud⁶⁷⁸,Lo Wing-Yee⁶⁷,Hoheisel Jörg D⁹,Hamann Ute²

Affiliation:

1. Statistical Genetics Group, Institute of Medical Biometry & Informatics, University of Heidelberg, Heidelberg, 69120, Germany

2. Department of Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany

3. Genomics & Proteomics Core Facility, Microarray Unit, German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany

4. Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, 53113, Germany

5. Institute for Prevention & Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bochum, 44789, Germany

6. Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, 70376, Germany

7. Department of Clinical Pharmacology, University of Tübingen, Tübingen, 70376, Germany

8. German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany

9. Division of Functional Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany

Abstract

Aim: To identify DNA methylation biomarkers in peripheral blood samples from triple-negative breast cancer (TNBC) patients. Materials & methods: We conducted an epigenome-wide association study (EWAS): the most promising markers were identified in 233 TNBC case–control pairs (discovery set) and subsequently validated in an independent validation set (57 TNBC patients and 124 controls). Results: cg06588802 (LINC00299/ID2) showed a higher methylation in TNBC patients compared with controls (discovery set: 3% increase, p-value = 0.0009; validation set: 2% increase, p-value = 0.01). Consistent results at four neighboring methylation probes and the strong negative correlation (rho = -0.93) with LINC00299 expression add plausibility to this result. Conclusion: Hypermethylation of LINC00299 in peripheral blood may constitute a useful circulating biomarker for TNBC.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Genetics

Link

https://www.futuremedicine.com/doi/pdf/10.2217/epi-2018-0121

Reference51 articles.

1. Triple Negative Breast Cancer: From Molecular Portrait to Therapeutic Intervention

2. Triple-negative breast cancer

3. Triple-negative breast cancer and the potential for targeted therapy

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. LINC00299 polymorphisms rs891058, rs13395467, and rs13398375 reduce the risk of allergic rhinitis among the Chinese Han population;Gene;2023-12

2. The Intergenic Type LncRNA (LINC RNA) Faces in Cancer with In Silico Scope and a Directed Lens to LINC00511: A Step toward ncRNA Precision;Non-Coding RNA;2023-09-25

3. Exploiting Long Non-Coding RNAs and Circular RNAs as Pharmacological Targets in Triple-Negative Breast Cancer Treatment;Cancers;2023-08-20

4. Predictive Factors of Response to Immunotherapy in Lymphomas: A Multicentre Clinical Data Warehouse Study (PRONOSTIM);Cancers;2023-08-09

5. LncRNA T376626 is a promising serum biomarker and promotes proliferation, migration, and invasion via binding to LAMC2 in triple-negative breast cancer;Gene;2023-04